

Tsai Larry
Form 3
January 04, 2018

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Tsai Larry

(Last)

(First)

(Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

12/29/2017

3. Issuer Name and Ticker or Trading Symbol

TETRAPHASE PHARMACEUTICALS INC [TTPH]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

___ Director ___ 10% Owner

X Officer ___ Other

(give title below) (specify below)

Chief Medical Officer

6. Individual or Joint/Group

Filing(Check Applicable Line)

X Form filed by One Reporting Person

___ Form filed by More than One Reporting Person

C/OTETRAPHASE
PHARMACEUTICALS,Â 480
ARSENAL WAY

(Street)

WATERTOWN,Â MAÂ 02472

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Common Stock

28,166

D

Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date
(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)

4. Conversion or Exercise Price of Derivative

5. Ownership Form of Derivative Security:

6. Nature of Indirect Beneficial Ownership
(Instr. 5)

Edgar Filing: Tsai Larry - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option (Right to Buy)	Â (1)	03/31/2024	Common Stock	60,000	\$ 11.3	D	Â
Employee Stock Option (Right to Buy)	Â (2)	01/06/2025	Common Stock	29,000	\$ 39.94	D	Â
Employee Stock Option (Right to Buy)	Â (3)	01/05/2026	Common Stock	20,000	\$ 8.47	D	Â
Employee Stock Option (Right to Buy)	Â (4)	01/29/2027	Common Stock	50,000	\$ 3.69	D	Â
Restricted Stock Units	Â (5)	Â (5)	Common Stock	8,000	\$ (6)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Tsai Larry C/OTETRAPHAASE PHARMACEUTICALS 480 ARSENAL WAY WATERTOWN,Â MAÂ 02472	Â	Â	Â Chief Medical Officer	Â

Signatures

/s/Maria Stahl as Attorney-in-Fact for
Larry Tsai

01/04/2018

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests over four years. Twenty-five percent (25%) of the shares vested on April 1, 2015 and 6.25% of the shares will vest at the end of each successive three-month period thereafter.
- (2) Vests as to 6.25% of the shares on 4/7/2015 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/7/2019.
- (3) Vests as to 6.25% of the shares on 4/6/2016 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/6/2020.
- (4) Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/30/2021.
- (5) The restricted stock units vest in three equal installments on each of January 6, 2017, January 6, 2018 and January 6, 2019.
- (6) Each restricted stock unit represents a contingent right to receive one share of common stock of Tetrphase Pharmaceuticals, Inc. for no consideration.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.